This newslink doesn't exist or it was removed.
Go to Homempage.
MarketWatch USA Business January 31, 2024
The Aduhelm commercial program had been all but dead since 2022, when the Centers for Medicare & Medicaid Services (CMS) declined to offer Medicare coverage for the drug. Biogen had been continuing of Aduhelm, however, as a condition of the Food and Drug Administration’s... + más
Biogen Ends Development of Alzheimer’s Drug Aduhelm | MarketWatch
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes
The New York Times USA Health December 29, 2022
The Food and Drug Administration’s process for approving the Alzheimer’s drug Aduhelm, despite great uncertainty about whether it worked, was “rife with irregularities,” according to released on Thursday. The agency’s actions “raise serious concerns about F.D.A.’s... + más
Here's what disease does to brain, signs to look for: Alzheimer's Q&A | The Advocate
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
WPLG Local 10 USA Health January 31, 2024
Biogen will stop developing its Alzheimer’s treatment , a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.The drugmaker said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug... + más
ABC7 USA World December 30, 2022
A congressional investigation into the Food and Drug Administration's review process for an Alzheimer's treatment found that the agency deviated from its standard procedures to approve the Aduhelm drug with inconsistent data.Aduhelm is notable for being the first drug... + más
Alzheimer's drug approval by FDA 'rife with irregularities,' probe finds | Los Angeles Times
About iurex | Privacy Policy | Disclaimer |